Replimune says RP2 plus nivolumab posts 19.1% response rate in phase 1 advanced solid tumor trial

Replimune

Replimune

REPL

0.00
  • Replimune presented final first-in-human Phase 1 data for RP2, alone or with nivolumab, in advanced solid tumors at the 2026 ASCO meeting.
  • Results showed tumor shrinkage in a meaningful share of heavily pretreated patients, with responses lasting for extended periods in some cases.
  • Activity was seen beyond injected tumors, supporting a broader immune effect that could expand RP2’s addressable use across metastatic disease.
  • Safety looked consistent with expectations, with no unexpected severe treatment-related events reported.
  • The readout supports a randomized Phase 2/3 study of RP2 with nivolumab in metastatic uveal melanoma (NCT06581406).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605310800PRIMZONEFULLFEED9729235) on May 31, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.